Sepracor looks to benefit its new owners
This article was originally published in Scrip
Dainippon Sumitomo Pharma's new US subsidiary, Sepracor, expects to be debt free by the end of this year and is forecasting full-year non-GAAP revenues of $1.23-1.28 billion, compared with $1.29 billion in 2008.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.